These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 35499745)

  • 1. Targeting DNA topoisomerase IIα (TOP2A) in the hypoxic tumour microenvironment using unidirectional hypoxia-activated prodrugs (uHAPs).
    Smith PJ; McKeown SR; Patterson LH
    IUBMB Life; 2023 Jan; 75(1):40-54. PubMed ID: 35499745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs.
    Phillips RM
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):441-57. PubMed ID: 26811177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring hypoxic biology to improve radiotherapy outcomes.
    Li C; Wiseman L; Okoh E; Lind M; Roy R; Beavis AW; Pires IM
    Expert Rev Mol Med; 2022 Apr; 24():e21. PubMed ID: 35586915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The unidirectional hypoxia-activated prodrug OCT1002 inhibits growth and vascular development in castrate-resistant prostate tumors.
    Nesbitt H; Worthington J; Errington RJ; Patterson LH; Smith PJ; McKeown SR; McKenna DJ
    Prostate; 2017 Nov; 77(15):1539-1547. PubMed ID: 28944496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AQ4N: a new approach to hypoxia-activated cancer chemotherapy.
    Patterson LH; McKeown SR
    Br J Cancer; 2000 Dec; 83(12):1589-93. PubMed ID: 11104551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing the therapeutic response of tumors to hypoxia-targeted prodrugs with an in silico approach.
    Yilmaz D; Tuzer M; Unlu MB
    Math Biosci Eng; 2022 Aug; 19(11):10941-10962. PubMed ID: 36124576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoxia Activated Prodrugs: Factors Influencing Design and Development.
    Liang D; Miller GH; Tranmer GK
    Curr Med Chem; 2015; 22(37):4313-25. PubMed ID: 26487420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Precise gliomas therapy: Hypoxia-activated prodrugs sensitized by nano-photosensitizers.
    Zhang H; Shi C; Han F; Li M; Ma H; Sui R; Long S; Sun W; Du J; Fan J; Piao H; Peng X
    Biomaterials; 2022 Oct; 289():121770. PubMed ID: 36075142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospects for hypoxia-based drug delivery platforms for the elimination of advanced metastatic tumors: From 3D modeling to clinical concepts.
    Shahpouri M; Adili-Aghdam MA; Mahmudi H; Jaymand M; Amoozgar Z; Akbari M; Hamblin MR; Jahanban-Esfahlan R
    J Control Release; 2023 Jan; 353():1002-1022. PubMed ID: 36516901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro radiosensitization of breast cancer with hypoxia-activated prodrugs.
    Aiyappa-Maudsley R; Elsalem L; Ibrahim AIM; Pors K; Martin SG
    J Cell Mol Med; 2022 Aug; 26(16):4577-4590. PubMed ID: 35841287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Programmable therapeutic nanoscale covalent organic framework for photodynamic therapy and hypoxia-activated cascade chemotherapy.
    He H; Du L; Xue H; Wu J; Shuai X
    Acta Biomater; 2022 Sep; 149():297-306. PubMed ID: 35811069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigational Hypoxia-Activated Prodrugs: Making Sense of Future Development.
    Su MX; Zhang LL; Huang ZJ; Shi JJ; Lu JJ
    Curr Drug Targets; 2019; 20(6):668-678. PubMed ID: 30468124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of hypoxia-activated prodrugs in combination with radiation therapy: An
    Meaney C; Powathil GG; Yaromina A; Dubois LJ; Lambin P; Kohandel M
    Math Biosci Eng; 2019 Jul; 16(6):6257-6273. PubMed ID: 31698561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent.
    Patterson LH; McKeown SR; Ruparelia K; Double JA; Bibby MC; Cole S; Stratford IJ
    Br J Cancer; 2000 Jun; 82(12):1984-90. PubMed ID: 10864207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leveraging Hypoxia-Activated Prodrugs to Prevent Drug Resistance in Solid Tumors.
    Lindsay D; Garvey CM; Mumenthaler SM; Foo J
    PLoS Comput Biol; 2016 Aug; 12(8):e1005077. PubMed ID: 27560187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypoxia-activated prodrug derivatives of anti-cancer drugs: a patent review 2006 - 2021.
    Anduran E; Dubois LJ; Lambin P; Winum JY
    Expert Opin Ther Pat; 2022 Jan; 32(1):1-12. PubMed ID: 34241566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting hypoxia in solid and haematological malignancies.
    Harris B; Saleem S; Cook N; Searle E
    J Exp Clin Cancer Res; 2022 Nov; 41(1):318. PubMed ID: 36320041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of hypoxia-activated prodrugs in cancer therapy.
    Denny WA
    Lancet Oncol; 2000 Sep; 1(1):25-9. PubMed ID: 11905684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions.
    Chen Z; Han F; Du Y; Shi H; Zhou W
    Signal Transduct Target Ther; 2023 Feb; 8(1):70. PubMed ID: 36797231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting Hypoxia: Hypoxia-Activated Prodrugs in Cancer Therapy.
    Li Y; Zhao L; Li XF
    Front Oncol; 2021; 11():700407. PubMed ID: 34395270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.